Your session is about to expire
← Back to Search
CAR T-Cell Therapy for Prostate Cancer
Study Summary
This trial is to study a new cancer treatment and to see if it is safe and works well.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have severe heart problems as defined by the NYHA.I do not have a condition that increases risk of severe immune or nerve side effects.My tumor shows high PSMA levels on a biopsy.My cancer has spread to my bones or other parts of my body and can be seen on scans.I haven't had immune therapy for cancer in the last 2 months, except for cancer vaccines.I have had a cancer other than prostate cancer that was not cured, within the last 3 years.My PSA levels are increasing, but I have no signs of cancer spread on scans.I am on a low dose of steroids, not more than 10mg of prednisone daily.I have had more than 4 treatments for advanced prostate cancer.I have spinal cord issues due to cancer spread to my spine.I have an active autoimmune disease or a history of severe autoimmune disease.I do not have active hepatitis B, C, or HIV.I have had treatment for advanced prostate cancer that no longer responds to hormonal therapy.My kidney and liver functions are within normal ranges.My prostate cancer is worsening despite low testosterone levels.My blood counts are within the required range and I don't need blood transfusions.My prostate cancer has spread and is not responding to hormone therapy.I am fully active or can carry out light work.I am 18 years old or older.I currently have an infection.
- Group 1: Cohort 2
- Group 2: Cohort 3
- Group 3: Cohort -3
- Group 4: Cohort 4
- Group 5: Cohort 1
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What applications do CART-PSMA-TGFβRDN cells typically facilitate?
"Patients with multiple sclerosis, mixed-cell type lymphoma, and acute myelocytic leukemia can be treated using CART-PSMA-TGFβRDN cells."
Can new participants still join this experiment?
"Affirmative, the clinical trial information posted to clinicaltrials.gov shows that this medical experiment is still searching for participants since its initial launch on March 8th 2017. 19 individuals are needed from a single site before recruitment ends and last edits were made on March 17th 2022."
What experiments have been done to evaluate the effectiveness of CART-PSMA-TGFβRDN cells?
"Presently, 816 individual research studies are being conducted with CART-PSMA-TGFβRDN cells. Of these investigations, 154 have progressed to Phase 3 clinical trials. Though Philadelphia is the hub for studying this treatment, there exist 27827 sites running such experiments worldwide."
Are CART-PSMA-TGFβRDN cells an innocuous option for individuals seeking medical treatment?
"Limited data on CART-PSMA-TGFβRDN cells' efficacy and safety warrants a score of 1."
How many participants is this research endeavor accommodating?
"Affirmative. The information posted on clinicaltrials.gov reveals that this research is still open to applicants, with the initial posting being made on March 8th 2017 and last updated on March 17th 2022. 19 individuals are sought at one study location."
Share this study with friends
Copy Link
Messenger